Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies
- PMID: 11801466
Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies
Abstract
Background and objectives: Myelodysplastic syndrome (MDS), secondary acute myeloid leukemia (sAML) and clonal karyotypic abnormalities, have been recognized as relatively frequent and potentially serious complications of autologous peripheral blood progenitor cell transplantation (PBPCT) for Hodgkin's disease (HD), non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).
Design and methods: We analyzed 66 patients, undergoing PBPCT for HD, NHL, MM or chronic lymphocytic leukemia (CLL). Patients reported in this study had to be in continuous complete remission after transplantation without receiving chemo-radiotherapy or other biological response modifiers, had to show absence of cytogenetic abnormalities and myelodysplastic features at transplantation and had to have at least 12 months of follow-up. We evaluated the bone marrow, peripheral blood, cytogenetics and clonality (HUMARA) 12 months after the transplant and thereafter every 12 months or every 6 months if lineage dysplasia, clonal or cytogenetic abnormalities were detected.
Results: We did not observe MDS/sAML, according to the FAB classification, in 163 assessments of 66 patients over a median follow-up of 25 months (range 12-106) after PBPCT. Twelve patients showed lineage dysplasia: six patients had dyserythropoiesis, 2 patients dysgranulopoiesis, one dysmegakaryocytopoiesis, two patients showed double lineage dysplasia (erythroid and granulocytic), and one patient showed dysgranulopoiesis at the first control acquiring dyserythropoiesis at the next follow-up. We found three cytogenetic abnormalities in the absence of concomitant dysplastic features: transient -5q, -Y, fra(10)(q25). The female patient with the cytogenetic abnormality -5q showed transient unbalanced clonality by HUMARA assay; further controls documented normalization of both clonality and cytogenetics.
Interpretation and conclusions: The occurrence of MDS/sAML depends on a variety of risk factors such as the number and type of prior courses of chemo-radiotherapy, total body irradiation in conditioning regimen, cytogenetic and morphologic alterations prior to transplant. This may account for the difference in reporting MDS/sAML after transplantation. The lack of exposure to recognized risk factors for MDS/sAML in our patients may account for the absence of this complication in this study. We consider that the use of stringent morphologic criteria, especially during the first period after PBPCT, combined with cytogenetic, clonality and FISH analyses are necessary for a correct diagnosis of MDS and to overcome the limitations of the FAB and WHO classifications in this setting.
Similar articles
-
Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.Haematologica. 2000 Apr;85(4):403-9. Haematologica. 2000. PMID: 10756367
-
Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.Bone Marrow Transplant. 2000 Jun;25(11):1203-8. doi: 10.1038/sj.bmt.1702416. Bone Marrow Transplant. 2000. PMID: 10849534
-
Physician Education: Myelodysplastic Syndrome.Oncologist. 1996;1(4):284-287. Oncologist. 1996. PMID: 10388004
-
Acute erythroid neoplastic proliferations. A biological study based on 62 patients.Haematologica. 2002 Feb;87(2):148-53. Haematologica. 2002. PMID: 11836165 Review.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
Myelodysplasia-associated immunophenotypic alterations of bone marrow cells in myeloma: are they present at diagnosis or are they induced by lenalidomide?Haematologica. 2012 Oct;97(10):1608-11. doi: 10.3324/haematol.2012.064121. Epub 2012 Apr 17. Haematologica. 2012. PMID: 22511492 Free PMC article.
-
A case of lenalidomide-dependent myelodysplastic syndrome.Blood Adv. 2017 Jun 30;1(16):1238-1242. doi: 10.1182/bloodadvances.2017006114. eCollection 2017 Jul 11. Blood Adv. 2017. PMID: 29296763 Free PMC article.
-
Isolated clonal cytogenetic abnormalities after high-dose therapy.Biol Blood Marrow Transplant. 2014 Aug;20(8):1130-8. doi: 10.1016/j.bbmt.2014.03.033. Epub 2014 Apr 13. Biol Blood Marrow Transplant. 2014. PMID: 24732780 Free PMC article.
-
Therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplantation in lymphoma patients.Cancer Biol Ther. 2013 Dec;14(12):1077-88. doi: 10.4161/cbt.26342. Epub 2013 Oct 18. Cancer Biol Ther. 2013. PMID: 24025414 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials
Miscellaneous